Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UTA2-1 peptide-loaded PD-L-silenced donor dendritic cell vaccine after allogeneic stem cell transplantation
NL-OMON44197Phase 2Withdrawn
- Sponsor
- Vrije University Medical Center
- Start
- Jan 2018
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of UTA2-1 peptide-loaded PD-L-silenced donor dendritic cell vaccine in multiple myeloma (MM), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), non-Hodgkin lymphoma (NHL) and 1 more, sponsored by Vrije University Medical Center. Primary endpoints: Toxicity and feasibility of vaccination and Immune status and UTA2-1-specific T-cell response. Planned start Jan 2018; status: withdrawn.
02
Drugs
UTA2-1 peptide-loaded PD-L-silenced donor dendritic cell vaccine
03
Conditions
multiple myeloma (MM)chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)non-Hodgkin lymphoma (NHL)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NL-OMON44197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44197.